Recent Advancements in the Development of Next-Generation Dual-Targeting Antibacterial Agents

Abstract

DNA gyrase and topoisomerase IV are validated targets for developing dual-targeting antibacterial agents. The development of novel molecules targeting both enzymes has gained tremendous importance in circumventing the development of bacterial resistance. In the present review, we highlight the recent developments and discovery of dual-targeting inhibitors over the last five years. The structure-activity relationship, molecular docking analysis, and pharmacological activity are presented to facilitate the rational design and development of novel dual-targeting inhibitors to bridge the gap in antibiotic drug discovery.

Article information

Article type
Review Article
Submitted
28 Nov 2024
Accepted
03 Feb 2025
First published
05 Feb 2025

RSC Med. Chem., 2025, Accepted Manuscript

Recent Advancements in the Development of Next-Generation Dual-Targeting Antibacterial Agents

F. A. Sofi, M. ., M. H. Masoodi and N. Tabassum, RSC Med. Chem., 2025, Accepted Manuscript , DOI: 10.1039/D4MD00934G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements